Strides Pharma Science’s step?down wholly owned subsidiary -- Strides Pharma Global Pte, Singapore has received approval for Loratadine Softgel Capsules, 10 mg (OTC) from the United States Food & Drug Administration (USFDA). The product is a generic version of Claritin Liqui?Gels Capsules, 10 mg, of Bayer HealthCare LLC.
Loratadine Softgel Capsules, 10 mg (OTC) is part of Strides niche and small volume product portfolio with limited competition in the US private label market. According to IRi data, the US market for Loratadine Softgel Capsules, 10 mg (OTC) is approximately $50 million with only one other generic approval. The product will be manufactured at the company’s oral dosage facility at Bangalore.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.
